Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy?

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 623-631

  Callaghan, Richard ^a   Luk, Frederick ^b   Bebawy, Mary ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; TARIQUIDAR; VERAPAMIL;

CANCER RESISTANCE; DRUG DELIVERY SYSTEM; HUMAN; MEMBRANE MICROPARTICLE; MULTIDRUG RESISTANCE; NANOENCAPSULATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; SUBSTRATE SPECIFICITY;

EID: 84896131650     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056176     Document Type: Short Survey

References (167)

1. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, and Balis F, et al. (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574-3582.
2. Andreev OA, Engelman DM, and Reshetnyak YK (2010) pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol Membr Biol 27:341-352.
3. Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, and Pavan A (2000) Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 18:163-170. (Pubitemid 32165250)
4. AntonyakMA, Wilson KF, and Cerione RA (2012) R(h)oads to microvesicles. Small GTPases 3:219-224.
5. Bates SE, Currier SJ, Alvarez M, and Fojo AT (1992) Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31:6366-6372.
6. Bebawy M and Chetty M (2008) Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 30:183-188. (Pubitemid 351196953)
7. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, and Grau GE (2009) Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 23: 1643-1649.
8. Bebawy M, Morris MB, and Roufogalis BD (2001) Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer 85:1998-2003. (Pubitemid 34775339)
9. Bech-Hansen NT, Till JE, and Ling V (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol 88:23-31.
10. Bellocq NC, Pun SH, Jensen GS, and Davis ME (2003) Transferrin- containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14:1122-1132. (Pubitemid 37449039)
11. Bentley J, Bell SE, Quinn DM, Kellett GL, and Warr JR (1996) 2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res 8:77-84.
12. Bradshaw DM and Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16:3674-3690. (Pubitemid 28506783)
13. Breier A, Gibalova L, Seres M, Barancik M, and Sulova Z (2013) New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 13:159-170.
14. Broxterman HJ, Pinedo HM, Kuiper CM, Kaptein LC, Schuurhuis GJ, and Lankelma J (1988) Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J 2:2278-2282.
15. Bui T and Thompson CB (2006) Cancer's sweet tooth. Cancer Cell 9:419-420. (Pubitemid 43832194)
16. Burnier L, Fontana P, Kwak BR, and Angelillo-Scherrer A (2009) Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 101:439-451.
17. Callaghan R, Crowley E, Potter S, and Kerr ID (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48:365-378.
18. Callaghan R and Riordan JR (1995) Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. Biochim Biophys Acta 1236:155-162.
19. Cambón A, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, Barbosa S, Taboada P, and Mosquera V (2013) Cytocompatibility and P-glycoprotein inhibition of block copolymers: structure-activity relationship. Mol Pharm 10:3232-3241.
20. Cambón A, Rey-Rico A, Barbosa S, Soltero JF, Yeates SG, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, and Taboada P, et al. (2013a) Poly(styrene oxide)-poly(ethylene oxide) block copolymers: From "classical" chemotherapeutic nanocarriers to active cell-response inducers. J Control Release 167:68-75.
21. Cambón A, Rey-Rico A, Mistry D, Brea J, Loza MI, Attwood D, Barbosa S, Alvarez-Lorenzo C, Concheiro A, and Taboada P, et al. (2013b) Doxorubicin-loaded micelles of reverse poly (butylene oxide)-poly(ethylene oxide)-poly(butylene oxide) block copolymers as efficient "active" chemotherapeutic agents. Int J Pharm 445:47-57.
22. Cano-Gauci DF and Riordan JR (1987) Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol 36:2115-2123.
23. Chambers TC, McAvoy EM, Jacobs JW, and Eilon G (1990) Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265:7679-7686.
24. Chambers TC, Pohl J, Raynor RL, and Kuo JF (1993) Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268:4592-4595. (Pubitemid 23081564)
25. Chambers TC, Zheng B, and Kuo JF (1992) Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 41:1008-1015. (Pubitemid 23026098)
26. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, and Roninson IB (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389. (Pubitemid 17210152)
27. Chen KG and Sikic BI (2012) Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18:1863-1869.
28. Chen L, Li Y, Yu H, Zhang L, and Hou T (2012) Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17:343-351.
29. Choi YS, Lee JY, Suh JS, Lee SJ, Yang VC, Chung CP, and Park YJ (2011) Cell penetrating peptides for tumor targeting. Curr Pharm Biotechnol 12:1166-1182.
30. Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat MB, Scambia G, and Rotilio D (2009) Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res 8:1902-1912.
31. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654. (Pubitemid 23012438)
32. Combes V, Coltel N, Faille D, Wassmer SC, and Grau GE (2006) Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int J Parasitol 36:541-546. (Pubitemid 44275316)
33. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, and Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387-3394. (Pubitemid 34651384)
34. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287. (Pubitemid 20266126)
35. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698. (Pubitemid 19037807)
36. Cornwell MM, Pastan I, and Gottesman MM (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166-2170. (Pubitemid 17102655)
37. Crowley E, McDevitt CA, and Callaghan R (2010) Generating inhibitors of P-glycoprotein: where to, now? Methods Mol Biol 596:405-432.
38. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, and Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424. (Pubitemid 19098134)
39. Daum N, Tscheka C, Neumeyer A, and Schneider M (2012) Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4:52-65.
40. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, and van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440-6449. (Pubitemid 350075034)
41. Diddens H, Niethammer D, and Jackson RC (1983) Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43:5286-5292. (Pubitemid 14230140)
42. Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, and Pavan A (1999) Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 17:131-140. (Pubitemid 29335439)
43. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670. (Pubitemid 29018757)
44. Du J-Z, Mao C-Q, Yuan Y-Y, Yang X-Z, and Wang J (2013) Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol Adv DOI: 10.1016/j.biotechadv.2013.08.002.
45. Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, DeWolf W, and Carvalho AC (1983) Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43:4434-4442. (Pubitemid 13041884)
46. Ekins S and Erickson JA (2002) A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30:96-99. (Pubitemid 34016946)
47. El-Sayed IH, Huang X, and El-Sayed MA (2006) Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 239:129-135. (Pubitemid 43946581)
48. Ferretti A, Chen LL, Di Vito M, Barca S, Tombesi M, Cianfriglia M, Bozzi A, Strom R, and Podo F (1993) Pentose phosphate pathway alterations in multi-drug resistant leukemic T-cells: 31P NMR and enzymatic studies. Anticancer Res 13:867-872. (Pubitemid 23247428)
49. Ferté J (2000) Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267:277-294.
50. Freyssinet JM (2003) Cellular microparticles: what are they bad or good for? J Thromb Haemost 1:1655-1662.
51. Freyssinet JM and Toti F (2010) Formation of procoagulant microparticles and properties. Thromb Res 125 (Suppl 1):S46-S48.
52. Gabizon A and Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 (Suppl 4):15-21. (Pubitemid 27487791)
53. Gao W, Chan JM, and Farokhzad OC (2010) pH-Responsive nanoparticles for drug delivery. Mol Pharm 7:1913-1920.
54. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
55. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, and Gottesman MM (1996) Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271:1708-1716.
56. Germann UA, Chambers TC, Ambudkar SV, Pastan I, and Gottesman MM (1995) Effects of phosphorylation of P-glycoprotein on multidrug resistance. J Bioenerg Biomembr 27:53-61.
57. Gillies RJ and Gatenby RA (2007) Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr 39:251-257. (Pubitemid 47619378)
58. Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, and Vittorelli ML (1997) Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272:17216-17222. (Pubitemid 27289836)
59. Goda K, Nagy H, Mechetner E, Cianfriglia M, and Szabó G, Jr (2002) Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells. Eur J Biochem 269:2672-2677. (Pubitemid 34595633)
60. Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, Brimacombe KR, Hall MD, Griffiths G, and Gottesman MM (2011) Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem 54:4987-4997.
61. Gong J, Jaiswal R, Mathys JM, Combes V, Grau GE, and Bebawy M (2012) Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 38:226-234.
62. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, and Higgins CF (1996) Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271:13668-13674. (Pubitemid 26185417)
63. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58. (Pubitemid 37328807)
64. Gros P, Croop J, and Housman D (1986) Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-380. (Pubitemid 17210151)
65. Gupta RS (1985) Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep 69:515-521.
66. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, and Kittel A, et al. (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68:2667-2688.
67. Hall JB, Dobrovolskaia MA, Patri AK, and McNeil SE (2007) Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) 2:789-803.
68. Hall MD, Brimacombe KR, Varonka MS, Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, and Fales HM, et al. (2011) Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem 54:5878-5889.
69. Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, and Kéri G (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587:318-325. (Pubitemid 34655800)
70. Herman TS, Cress AE, and Gerner EW (1979) Collateral sensitivity to methotrexate in cells resistant to adriamycin. Cancer Res 39:1937-1942. (Pubitemid 9184981)
71. Higgins CF and Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17:18-21.
72. Homolya L, Holló Z, Germann UA, Pastan I, Gottesman MM, and Sarkadi B (1993) Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493-21496. (Pubitemid 23320634)
73. Horstman LL and Ahn YS (1999) Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 30:111-142. (Pubitemid 29232249)
74. Hua MY, Yang HW, Liu HL, Tsai RY, Pang ST, Chuang KL, Chang YS, Hwang TL, Chang YH, and Chuang HC, et al. (2011) Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials 32:8999-9010.
75. Huang TH, Bebawy M, Tran VH, and Roufogalis BD (2007) Specific reversal of multidrug resistance to colchicine in CEM/VLB(100) cells by Gynostemma pentaphyllum extract. Phytomedicine 14:830-839. (Pubitemid 350016828)
76. Hugel B, Martínez MC, Kunzelmann C, and Freyssinet JM (2005) Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20:22-27. (Pubitemid 40363367)
77. Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, Grau GE, and Bebawy M (2012a) Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 26: 420-429.
78. Jaiswal R, Luk F, Dalla PV, Grau GE, and Bebawy M (2013) Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS ONE 8: e61515.
79. Jaiswal R, Luk F, Gong J, Mathys JM, Grau GE, and Bebawy M (2012b) Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol Cancer DOI: 10.1186/1476-4598-11-37 [published ahead of print].
80. Jensen PB, Roed H, Sehested M, Demant EJ, Vindeløv L, Christensen IJ, and Hansen HH (1992) Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity. Cancer Chemother Pharmacol 31:46-52.
81. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455:152-162.
82. Kartner N, Evernden-Porelle D, Bradley G, and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820-823. (Pubitemid 15003741)
83. Karwatsky J, Lincoln MC, and Georges E (2003) A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 42:12163-12173. (Pubitemid 37296492)
84. Ke AB, Eyal S, Chung FS, Link JM, Mankoff DA, Muzi M, and Unadkat JD (2013) Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J Nucl Med 54:437-446.
85. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, and Gho YS (2002) Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 62:6312-6317. (Pubitemid 35244486)
86. Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, and O'Kennedy R (2009) Molecular and magnetic resonance imaging: The value of immunoliposomes. Adv Drug Deliv Rev 61:1402-1411.
87. Labrie P, Maddaford SP, Lacroix J, Catalano C, Lee DK, Rakhit S, and Gaudreault RC (2007) In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). Bioorg Med Chem 15:3854-3868. (Pubitemid 46661801)
88. Ledoux S, Yang R, Friedlander G, and Laouari D (2003) Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res 63:7284-7290. (Pubitemid 37413469)
89. Leonard GD, Fojo T, and Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411-424. (Pubitemid 37238869)
90. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237. (Pubitemid 40552845)
91. Lu JF, Luk F, Gong J, Jaiswal R, Grau GE, and Bebawy M (2013) Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res 76:77-83.
92. Magadala P and Amiji M (2008) Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J 10:565-576.
93. Marsh W and Center MS (1987) Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res 47:5080-5086. (Pubitemid 17146476)
94. McClean S and Hill BT (1993) Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer 29A:2243-2248. (Pubitemid 24053001)
95. McHugh K and Callaghan R (2008) Clinical trials on MDR reversal agents, in Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment (Colabufo NA, ed) pp 321-353, Research Signpost, Kerala.
96. McNeil SE (2009) Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:264-271.
97. Mellado W and Horwitz SB (1987) Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 26:6900-6904. (Pubitemid 18006248)
98. Mellor HR and Callaghan R (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81:275-300. (Pubitemid 351666917)
99. Merino V, Jiménez-Torres NV, and Merino-Sanjuán M (2004) Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 1:203-212.
100. Meyers MB (1989) Protein phosphorylation in multidrug resistant Chinese hamster cells. Cancer Commun 1:233-241.
101. Milane L, Duan Z, and Amiji M (2011) Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 6:e24075.
102. Modok S, Mellor HR, and Callaghan R (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6:350-354. (Pubitemid 44026037)
103. Morel O, Toti F, Hugel B, and Freyssinet JM (2004) Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 11:156-164. (Pubitemid 38952003)
104. Muller C, Laurent G, and Ling V (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 163:538-544.
105. Nakagawa-Goto K, Bastow KF, Chen TH, Morris-Natschke SL, and Lee KH (2008) Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. J Med Chem 51:3297-3303. (Pubitemid 351821888)
106. Niso M, Abate C, Contino M, Ferorelli S, Azzariti A, Perrone R, Colabufo NA, and Berardi F (2013) Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity. ChemMedChem 8:2026-2035.
107. Nomura S, Inami N, Kimura Y, Omoto S, Shouzu A, Nishikawa M, and Iwasaka T (2007) Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 21:38-44. (Pubitemid 44929342)
108. Nomura S, Ozaki Y, and Ikeda Y (2008) Function and role of microparticles in various clinical settings. Thromb Res 123:8-23.
109. Nomura S, Shouzu A, Omoto S, Nishikawa M, and Iwasaka T (2005) Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 19:551-557. (Pubitemid 40946040)
110. Nomura S, Takahashi N, Inami N, Kajiura T, Yamada K, Nakamori H, and Tsuda N (2004) Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 174:329-335. (Pubitemid 38597090)
111. Oguro M, Seki Y, Okada K, and Andoh T (1990) Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother 44:209-216. (Pubitemid 20326782)
112. Oku N and Namba Y (1994) Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 11:231-270.
113. Orr GA, Han EK, Browne PC, Nieves E, O'Connor BM, Yang CP, and Horwitz SB (1993) Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites. J Biol Chem 268: 25054-25062. (Pubitemid 23335528)
114. Ozols RF, Cunnion RE, Klecker RW, Jr, Hamilton TC, Ostchega Y, Parrillo JE, and Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647. (Pubitemid 17062504)
115. Paigen K (1962) The prediction of growth-inhibitory drug combinations showing enhanced differential toxicity and collateral sensitivity. Cancer Res 22:1290-1296.
116. Pekcec A, Unkrüer B, Schlichtiger J, Soerensen J, Hartz AMS, Bauer B, van Vliet EA, Gorter JA, and Potschka H (2009) Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 330:939-947.
117. Penet MF, Abou-Hamdan M, Coltel N, Cornille E, Grau GE, de Reggi M, and Gharib B (2008) Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci USA 105:1321-1326. (Pubitemid 351397051)
118. Peng H, Yuan X, Shi R, Wei X, Ren S, Yan C, Ding Y, Lin Y, Fan D, and Yang M, et al. (2013) PHII-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR- counterpart K562/A02 through producing reactive oxygen species. Eur J Pharmacol 718:459-468.
119. Peng XC, Gong FM, Wei M, Chen X, Chen Y, Cheng K, Gao F, Xu F, Bi F, and Liu JY (2010) Proteomic analysis of cell lines to identify the irinotecan resistance proteins. J Biosci 35: 557-564.
120. Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859-1876.
121. Petersen AL, Hansen AE, Gabizon A, and Andresen TL (2012) Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev 64:1417-1435.
122. Pétriz J, Gottesman MM, and Aran JM (2004) An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv 1:43-56.
123. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, and Fleming DR, et al. (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682-691. (Pubitemid 41114904)
124. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, and Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-3980.
125. Richert ND, Aldwin L, Nitecki D, Gottesman MM, and Pastan I (1988) Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 27:7607-7613.
126. Riezman H, Woodman PG, van Meer G, and Marsh M (1997) Molecular mechanisms of endocytosis. Cell 91:731-738. (Pubitemid 28007730)
127. Righetti PG, Castagna A, Antonioli P, Cecconi D, Campostrini N, and Righetti SC (2005) Proteomic approaches for studying chemoresistance in cancer. Expert Rev Proteomics 2:215-228. (Pubitemid 40529860)
128. Robillard KR, Hoque T, and Bendayan R (2012) Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. J Pharmacol Exp Ther 340:96-108.
129. Roseblade A, Luk F, Rawling T, Ung A, Grau GE, and Bebawy M (2013) Cell-derived microparticles: new targets in the therapeutic management of disease. J Pharm Pharm Sci 16:238-253.
130. Sadasivan R, Morgan R, Fabian C, and Stephens R (1991) Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett 57:165-171.
131. Safa AR (1988) Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85:7187-7191.
132. Sarko D, Beijer B, Garcia Boy R, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, and Mier W (2010) The pharmacokinetics of cell-penetrating peptides. Mol Pharm 7:2224-2231.
133. Sato W, Yusa K, Naito M, and Tsuruo T (1990) Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 173:1252-1257.
134. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, and Gottesman MM (2012) Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15:62-69.
135. Shen D-Y, Zhang W, Zeng X, and Liu C-Q (2013) Inhibition of Wnt/b-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci 104: 1303-1308.
136. Shouzu A, Nomura S, Omoto S, Hayakawa T, Nishikawa M, and Iwasaka T (2004) Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus. Clin Appl Thromb Hemost 10:167-173. (Pubitemid 38490085)
137. Sladek NE, Low JE, and Landkamer GJ (1985) Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines. Cancer Res 45:625-629. (Pubitemid 15161058)
138. Smith CD and Zilfou JT (1995) Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270:28145-28152.
139. Staats J, Marquardt D, and Center MS (1990) Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. J Biol Chem 265:4084-4090.
140. Steinbach D and Legrand O (2007) ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21:1172-1176. (Pubitemid 46831804)
141. Sui H, Fan ZZ, and Li Q (2012) Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 40:426-435.
142. Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, and Duan Z (2010) Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS ONE 5:e10764.
143. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590. (Pubitemid 32448326)
144. Szybalski W and Bryson V (1952) Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol 64:489-499.
145. Tang T, Song X, Liu YF, and Wang WY (2013) PEITC reverse multi-drug resistance of human gastric cancer SGC7901/DDP cell line. Cell Biol Int DOI: 10.1002/cbin.10169.
146. Thews O, Dillenburg W, Fellner M, Buchholz HG, Bausbacher N, Schreckenberger M, and Rösch F (2010) Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer. Eur J Nucl Med Mol Imaging 37:1935-1942.
147. Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A, and Rahman A (1989) Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun 1:311-316.
148. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, and Sakurai Y (1983) Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43:2905-2910. (Pubitemid 13100565)
149. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730-4733. (Pubitemid 13205981)
150. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
151. Wang L, Meng Q, Wang C, Liu Q, Peng J, Huo X, Sun H, Ma X, and Liu K (2013) Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-κB signaling inhibition. J Nat Prod 76:909-914.
152. Wang XK and Fu LW (2010) Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab 11:618-628.
153. Wang Z, Chen Y, Liang H, Bender A, Glen RC, and Yan A (2011) P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model 51:1447-1456.
154. Wartenberg M, Gronczynska S, Bekhite MM, Saric T, Niedermeier W, Hescheler J, and Sauer H (2005) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113:229-240. (Pubitemid 39628313)
155. Wassmer SC, Cianciolo GJ, Combes V, and Grau GE (2005) Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med 2:e245.
156. Wattiaux R, Laurent N, Wattiaux-De Coninck S, and Jadot M (2000) Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 41:201-208. (Pubitemid 30122959)
157. Weiss J and Haefeli WE (2013) Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 41:484-487.
158. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906. (Pubitemid 44527826)
159. Xin Y, Yin F, Qi S, Shen L, Xu Y, Luo L, Lan L, and Yin Z (2013) Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation. Toxicol Lett 221:73-82.
160. Xu C, Li CY, and Kong AN (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268. (Pubitemid 44698742)
161. Yang H, Lou C, Xu M, Wu C, Miyoshi H, and Liu Y (2011) Investigation of folate-conjugated fluorescent silica nanoparticles for targeting delivery to folate receptor-positive tumors and their internalization mechanism. Int J Nanomedicine 6:2023-2032.
162. Yang JM, Chin KV, and Hait WN (1996) Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 56:3490-3494.
163. Yoshimura A, Kuwazuru Y, Sumizawa T, Ikeda S, Ichikawa M, Usagawa T, and Akiyama S (1989) Biosynthesis, processing and half-life of P-glycoprotein in a human multidrug-resistant KB cell. Biochim Biophys Acta 992:307-314. (Pubitemid 19220892)
164. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211.
165. Zhang W and Ling V (2000) Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 184:17-26. (Pubitemid 30349624)
166. Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL, Ren F, and Li GF (2013) Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS ONE 8:e71071.
167. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, and Tan M (2011) Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) 16:1844-1860.